Bonus BioGroup Ltd. (BBIXF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bonus BioGroup Ltd. (BBIXF) trades at $0.11 with AI Score 48/100 (Grade C). Bonus BioGroup Ltd. is a biotechnology company focused on developing tissue-regenerating bone grafts for skeletal disorders. Market cap: $128.47M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BBIXF: BBIXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BBIXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BBIXF: the 1 perspectives are evenly split.
How is this calculated? →Bonus BioGroup Ltd. (BBIXF) Healthcare & Pipeline Overview
Bonus BioGroup Ltd., based in Israel, is a biotechnology firm specializing in autologous cell-based bone regeneration technologies. Their focus on personalized bone grafts for skeletal disorders positions them in the regenerative medicine sector, with products targeting bone trauma, arthritis, and large bone defects.
What Is the Investment Thesis for BBIXF?
Bonus BioGroup presents a compelling, albeit high-risk, investment thesis centered on its autologous bone regeneration technology. The company's BonoFill products address a significant market need for personalized bone grafts, potentially reducing complications associated with traditional allografts. Key value drivers include successful clinical trials demonstrating the efficacy of BonoFill in treating skeletal disorders, regulatory approvals in key markets, and strategic partnerships for commercialization. However, the company's negative P/E ratio of -11.72 reflects its current lack of profitability, and the relatively low beta of 0.81 suggests lower volatility compared to the broader market. Growth catalysts include the advancement of its pipeline products, particularly the large vascularized bone grafts, and expansion into new geographic markets. The investment thesis hinges on Bonus BioGroup's ability to successfully navigate the regulatory landscape, secure funding for ongoing research and development, and effectively commercialize its products.
Based on FMP financials and quantitative analysis
BBIXF Key Highlights
- Market capitalization of $128.47M reflects the company's current valuation in the biotechnology sector.
- A P/E ratio of -11.72 indicates that the company is currently not profitable, common for biotechnology firms in the development stage.
- The company employs 49 individuals, suggesting a focused and lean operational structure.
- Development of BonoFill injectable bone graft targets a specific need in bone repair applications, including jaw bone cysts.
- Pipeline includes bone grafts for maxillofacial and orthopedic applications, indicating potential for future growth.
Who Are BBIXF's Competitors?
BBIXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.87 | -5.97% | $39.39M | 45 |
| CLIFF Cordlife Group Limited | $0.15 | +0.00% | $38.57M | 53 |
| CLYYF Celyad Oncology S.A. | $0.25 | +0.00% | $11.19M | 61 |
| ELVAF EvoNext Holdings S.A. | $2.15 | +0.00% | $15.50M | 42 |
| FNCH Finch Therapeutics Group, Inc. | $8.70 | +16.00% | $13.97M | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BBIXF's Key Strengths?
- Proprietary autologous cell-based bone regeneration technology.
- BonoFill products offer a personalized approach to bone repair.
- Focus on addressing unmet needs in skeletal disorders.
- Pipeline of innovative bone graft products.
What Are BBIXF's Weaknesses?
- Limited commercialization experience.
- Reliance on regulatory approvals for product launches.
- High research and development costs.
- Negative P/E ratio indicates current lack of profitability.
What Could Drive BBIXF Stock Higher?
- Clinical trial results for BonoFill in new orthopedic applications.
- Regulatory approvals for BonoFill in the United States and Europe.
- Development of novel nanomaterials technology for tissue regeneration.
- Advancement of large vascularized bone grafts.
- Strategic partnerships for commercialization.
What Are the Key Risks for BBIXF?
- Financial-distress signal — its Altman Z-Score of -28.09 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established bone graft companies.
- Regulatory hurdles and delays in product approvals.
- Technological advancements in alternative bone regeneration methods.
- High research and development costs.
- Reliance on regulatory approvals for product launches.
What Are the Growth Opportunities for BBIXF?
- Expansion of BonoFill product line: Bonus BioGroup has the opportunity to broaden the applications of its BonoFill injectable and pre-designed bone grafts. Targeting specific orthopedic procedures, such as spinal fusion or joint reconstruction, could significantly increase market penetration. The global bone graft market is projected to reach $6.2 billion by 2027, offering a substantial addressable market. Success will depend on clinical data supporting efficacy in these new applications and securing regulatory approvals.
- Development of novel nanomaterials technology: The company's research into nanomaterials for tissue regeneration presents a significant growth opportunity. Nanomaterials can enhance bone regeneration by providing a scaffold for cell attachment and promoting angiogenesis. The market for nanomaterials in regenerative medicine is expected to grow rapidly, driven by advancements in materials science and nanotechnology. Successful development and commercialization of nanomaterial-based bone grafts could provide Bonus BioGroup with a competitive advantage and access to a high-growth market segment.
- Advancement of large vascularized bone grafts: The development of large vascularized bone grafts represents a significant advancement in bone regeneration. These grafts have the potential to address large bone defects and improve outcomes in complex orthopedic procedures. The market for vascularized bone grafts is currently limited but is expected to grow as the technology matures and clinical evidence accumulates. Bonus BioGroup's expertise in cell-based therapies positions it to capitalize on this emerging market opportunity.
- Strategic partnerships for commercialization: Forming strategic partnerships with established orthopedic companies or distributors can accelerate the commercialization of Bonus BioGroup's products. These partnerships can provide access to established sales channels, marketing expertise, and regulatory support. The global orthopedic market is dominated by a few large players, and partnering with one of these companies could significantly increase Bonus BioGroup's market reach and revenue potential. Successful partnerships will depend on demonstrating the clinical and economic value of Bonus BioGroup's products.
- Geographic expansion into new markets: Expanding into new geographic markets, such as the United States and Europe, represents a significant growth opportunity for Bonus BioGroup. These markets have a large and growing demand for bone grafts, driven by the aging population and the increasing prevalence of skeletal disorders. However, entering these markets requires significant investment in regulatory approvals, clinical trials, and marketing. Bonus BioGroup will need to carefully assess the market potential and develop a comprehensive market entry strategy to succeed in these new geographies.
What Opportunities Does BBIXF Have?
- Expansion into new orthopedic and maxillofacial applications.
- Development of novel nanomaterials for tissue regeneration.
- Strategic partnerships with established orthopedic companies.
- Geographic expansion into the United States and Europe.
What Threats Does BBIXF Face?
- Competition from established bone graft companies.
- Regulatory hurdles and delays in product approvals.
- Technological advancements in alternative bone regeneration methods.
- Economic downturn impacting healthcare spending.
What Are BBIXF's Competitive Advantages?
- Proprietary autologous cell-based technology.
- Patented BonoFill bone graft products.
- Expertise in tissue regeneration and bone engineering.
- Focus on personalized medicine approach.
What Does BBIXF Do?
Founded in 1981 as Oceana Advanced Industries Ltd. and later rebranded as Bonus BioGroup Ltd., the company is dedicated to developing and commercializing advanced tissue-regenerating bone grafts. Their core technology centers around creating bone grafts from a patient's own cells, minimizing the risk of rejection and promoting faster healing. The company's flagship products include BonoFill injectable bone graft, designed for applications like jaw bone cysts, and BonoFill pre-designed bone graft, intended for repairing large and segmental bone defects. These products address a significant need in the treatment of skeletal disorders, offering a personalized approach to bone regeneration. Bonus BioGroup's pipeline includes bone grafts for maxillofacial and orthopedic applications, novel nanomaterials technology for tissue regeneration, and large vascularized bone grafts, indicating a commitment to expanding its product portfolio and addressing a broader range of clinical needs. Headquartered in Haifa, Israel, Bonus BioGroup is focused on advancing its technology and securing regulatory approvals to bring its innovative bone regeneration solutions to market.
What Products and Services Does BBIXF Offer?
- Develops tissue-regenerating bone grafts using a patient's own cells.
- Offers BonoFill injectable bone graft for bone repair applications.
- Provides BonoFill pre-designed bone graft for large and segmental bone defects.
- Focuses on treating skeletal disorders like bone trauma and arthritis.
- Researches novel nanomaterials technology for tissue regeneration.
- Develops large vascularized bone grafts for complex bone defects.
How Does BBIXF Make Money?
- Develops and manufactures autologous bone grafts.
- Commercializes bone grafts through direct sales or partnerships.
- Generates revenue from the sale of BonoFill products.
- Invests in research and development to expand its product pipeline.
What Industry Does BBIXF Operate In?
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant capital requirements. The market for bone grafts is driven by the increasing prevalence of skeletal disorders, trauma, and the aging population. Bonus BioGroup operates in the regenerative medicine segment, which is experiencing rapid growth due to advancements in cell-based therapies and personalized medicine. The competitive landscape includes companies developing synthetic bone grafts, allografts, and other regenerative technologies. Key trends include the shift towards minimally invasive procedures, the demand for biocompatible materials, and the focus on personalized treatment approaches. Bonus BioGroup's autologous cell-based technology positions it to capitalize on the trend towards personalized medicine in bone regeneration.
Who Are BBIXF's Key Customers?
- Orthopedic surgeons
- Maxillofacial surgeons
- Hospitals
- Clinics
How Bonus BioGroup Ltd. Is Valued
Bonus BioGroup Ltd. carries a market capitalization of $128.47M, placing it in the micro-cap category. Relative to its peer group, BBIXF's quantitative score of 48/100 is roughly in line with the peer average of 50/100.
Company Profile
Bonus BioGroup Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Haifa, IL. The company is led by CEO Shai Meretzki. BBIXF has traded publicly since 2019.
Key Financial Metrics
Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -7.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Bonus BioGroup Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.09 places it in the distress zone, a signal of elevated financial risk.
BBIXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates confidence in the company's future prospects, suggesting insiders believe in upcoming growth.
- Community sentiment has shifted positively as discussions around potential partnerships and innovative projects gain traction.
- The company's advancements in biotechnology have been well-received, with market chatter highlighting their unique offerings in a competitive landscape.
- Increased media coverage on Bonus BioGroup's impact on health solutions has sparked interest among retail investors.
Bear Case
- Concerns regarding regulatory hurdles in the biotech sector have dampened some investor enthusiasm, leading to cautious sentiment.
- Recent bearish commentary on social platforms reflects skepticism about the company's ability to scale its operations effectively.
- Market perception remains mixed, as some analysts question the sustainability of Bonus BioGroup's recent innovations amid competitive pressures.
- Insider selling activity in the past may raise red flags for some investors, causing hesitation about the company's long-term commitment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BBIXF Latest News
No recent news available for BBIXF.
BBIXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BBIXF.
Price Targets
Wall Street price target analysis for BBIXF.
BBIXF MoonshotScore
What does this score mean?
The MoonshotScore rates BBIXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shai Meretzki
CEO
Shai Meretzki serves as the CEO of Bonus BioGroup Ltd. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions in various companies, focusing on business development, strategic planning, and product commercialization. Meretzki's expertise spans across multiple therapeutic areas, including regenerative medicine and cell-based therapies. He is responsible for driving Bonus BioGroup's strategic vision and overseeing the company's research and development efforts.
Track Record: Under Shai Meretzki's leadership, Bonus BioGroup has focused on advancing its BonoFill product line and expanding its pipeline of bone graft products. Key milestones include securing regulatory approvals for BonoFill in select markets and initiating clinical trials for new applications. Meretzki has also overseen the company's efforts to develop novel nanomaterials technology for tissue regeneration and large vascularized bone grafts. His strategic decisions have been instrumental in positioning Bonus BioGroup as a leader in autologous cell-based bone regeneration.
BBIXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bonus BioGroup (BBIXF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may be subject to limited regulatory oversight and may not be required to provide audited financial statements. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, as the availability of information and regulatory scrutiny are significantly reduced.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements on the OTC Other tier.
- Potential for price manipulation due to low trading volumes.
- Higher risk of fraud or misrepresentation compared to major exchanges.
- Difficulty in obtaining accurate and timely financial information.
- Limited liquidity and wider bid-ask spreads.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Determine the company's capital structure and funding sources.
- Analyze the company's market capitalization and trading volume.
- Consult with a qualified financial advisor.
- Development of proprietary autologous cell-based bone regeneration technology.
- Focus on addressing unmet needs in skeletal disorders.
- Pipeline of innovative bone graft products.
- Experienced management team with expertise in biotechnology.
- Scientific publications or presentations supporting the efficacy of BonoFill products.
What Investors Ask About Bonus BioGroup Ltd. (BBIXF) — Healthcare
What does Bonus BioGroup Ltd. do?
Bonus BioGroup Ltd. is a biotechnology company specializing in the development of tissue-regenerating bone grafts. Their core technology revolves around creating personalized bone grafts from a patient's own cells, which minimizes the risk of rejection and promotes faster healing. The company's flagship products, BonoFill injectable and pre-designed bone grafts, target a range of skeletal disorders, including bone trauma, arthritis, and large bone defects. Bonus BioGroup is committed to advancing its technology and securing regulatory approvals to bring its innovative bone regeneration solutions to market.
What do analysts say about BBIXF stock?
As of 2026-03-17, formal analyst coverage of BBIXF is limited, likely due to its OTC listing and relatively small market capitalization. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability, which is common for biotechnology firms in the development stage. Growth considerations center around the successful advancement of its pipeline products, regulatory approvals in key markets, and strategic partnerships for commercialization. Investors should conduct their own thorough research and consider the inherent risks associated with investing in early-stage biotechnology companies.
What are the main risks for BBIXF?
The main risks for Bonus BioGroup Ltd. include competition from established bone graft companies, regulatory hurdles and delays in product approvals, and technological advancements in alternative bone regeneration methods. The company also faces risks associated with high research and development costs, reliance on regulatory approvals for product launches, and the potential for clinical trial failures. Additionally, its listing on the OTC Other tier carries inherent risks related to limited regulatory oversight, potential price manipulation, and difficulty in obtaining accurate and timely financial information.
What are the key factors to evaluate for BBIXF?
Bonus BioGroup Ltd. (BBIXF) holds an AI score of 48/100 (low). Not financial advice.
How frequently does BBIXF data refresh on this page?
BBIXF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BBIXF's recent stock price performance?
Bonus BioGroup Ltd. (BBIXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary autologous cell-based bone regeneration technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BBIXF overvalued or undervalued right now?
Valuing Bonus BioGroup Ltd. (BBIXF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BBIXF?
Before investing in Bonus BioGroup Ltd. (BBIXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for BBIXF may impact the accuracy of some data.
- OTC market investments carry higher risks than exchange-listed stocks.